Analyst II, R2R Operations at Bristol-Myers Squibb

Hyderabad, Telangana, India

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates must have a minimum of 3-5 years of experience in record-to-report accounting processes. Exceptional expertise in R2R accounting, a deep understanding of the business landscape, market trends, and industry dynamics are required. Excellent leadership skills are also necessary.

Responsibilities

The Analyst II, R2R Operations will support the execution of R2R accounting activities, including performing period-end close tasks such as account reconciliation QC, accounts receivable, accruals, and operational reporting. They will also prepare balance sheet control reconciliations, monitor internal customer satisfaction, complete period audits, and execute ad-hoc projects. This role involves managing R2R activities in collaboration with local markets and third-party providers, holding oneself and others to timelines and quality standards, and articulating material risks and opportunities.

Skills

Record-to-Report (R2R) accounting

Financial accounting

Business analysis

Market trends analysis

Leadership

Team motivation

Communication

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free